Prolonged Deleterious Influences of Chemotherapeutic Agent CPT-11 on Resident Peritoneal Macrophages and B1 Cells

Wen-Jing Bai1†, Chen-Guang Li1†, Cheng-Cheng Zhang1†, Li-Hui Xu2, Qiong-Zhen Zeng1, Bo Hu3, Zhou Hong1, Xian-Hui He1 and Dong-Yun Ouyang1*

1Department of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China, 2Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou, China, 3Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China

CPT-11 is a first-line chemotherapeutic agent for the treatment of colorectal cancer in clinic. Previous studies including ours have demonstrated that CPT-11 is, however, toxic to the intestinal epithelium and resident peritoneal macrophages. By interacting with B1 cells, the resident peritoneal macrophages play critical roles in the maintenance of gastrointestinal homeostasis. It remains therefore elusive whether these peritoneal innate immune cells could be rebuilt spontaneously or artificially after being impaired by CPT-11 administration. In this study, we found that mouse resident peritoneal macrophages, namely the large peritoneal macrophages (LPMs) with a CD11b+F4/80hiGATA6+ phenotype, and B1 (CD19+CD23−) cells were depleted by intraperitoneal (i.p.) CPT-11 treatment within 1 week, but reappeared from day 14 after CPT-11 treatment. However, the recovery processes of these innate immune cells were slow, as their counts could not be fully recovered even 2 months later, when compared with that of vehicle-treated control group. Interestingly, in the peritoneal cavity of the mice treated with CPT-11, the cell counts of LPMs and B1 cells were significantly increased after adoptive transfer with syngeneic peritoneal exudate cells (PECs) from healthy mice. Adoptive transfer with bone marrow cells also slightly increased, although not significantly, the cell counts of LPMs and B1 cells in CPT-11-treated mice. The survival rate of bacterial infected mice was significantly reduced by i.p. CPT-11 treatment in comparison with vehicle-treated or untreated control groups. Besides, oral administration of CPT-11 also had a delayed toxicity on the resident peritoneal macrophages. Our results suggest that CPT-11 has prolonged deleterious effects on peritoneal innate immune cells but adoptive transfer with PECs may accelerate their recovery processes, highlighting the potential of adoptive cell transfer as an avenue to counteract the adverse effects of this chemotherapeutic agent.

Keywords: CPT-11, resident peritoneal macrophages, peritoneal B1 cells, cytotoxicity, adoptive transfer

INTRODUCTION

There are several types of immune cells in the exudate of the peritoneal cavity, including macrophages and B cells, which play critical roles in defense against infections and in maintaining homeostasis of tissues where they reside (1, 2). Emerging evidence has indicated the phenotypic and functional diversities of these tissue-resident immune cells. For example, recent studies revealed that peritoneal...
macrophages are heterogeneous (3, 4). In mice, they can be further classified into two subpopulations according to their cell surface expression of F4/80 and MHC class II molecules. One subpopulation is constituted by large peritoneal macrophages (LPMs) with high levels of F4/80 but low levels of MHC class II, while the other is composed of small peritoneal macrophages (SPMs) with low levels of F4/80 but high levels of MHC class II (3). These two subpopulations are not only different in phenotypes but also in functions (3). It is generally believed that the LPMs are tissue-resident macrophages which are developed from yolk sac and are self-renewing, whereas the origin of SPMs is not quite clear (5, 6). Some studies have observed that the MHC II+ SPMs can be replenished by circulating monocytes (7); but others have indicated that SPMs are not present in the blood and they are phenotypically distinct from monocytes (6). Apart from macrophages, B cells in the peritoneal exudate are also heterogeneous (8). Both B1 and B2 cells are included, but the ratio of B1 cells is much higher in the peritoneal cavity when compared with those in other organs and compartments (e.g., blood). About 35–70% peritoneal B cells are B1 cells with a CD19+CD23− phenotype (9), which are largely innate immune cells and are also self-renewing in the peritoneal cavity (10).

In recent years, the functions of peritoneal macrophages and B1 cells, as well as their interactions with each other, have been extensively explored (6, 9, 11). It has been reported that GATA6, a transcriptional factor, is characteristically expressed in LPMs but not in SPMs (12). Under the regulation of retinoic acid, GATA6 directs the expression and secretion of TGF-β from peritoneal macrophages, which in turn stimulates B1 cells to migrate into the intestine and secrete IgA (9). Through such a mechanism, the peritoneal macrophages and B1 cells play important roles in the maintenance of the gastrointestinal homeostasis (11).

Previously, we have reported that CPT-11, a chemotherapeutic agent, can eliminate resident peritoneal macrophages by inducing apoptosis (13). CPT-11 is a first-line drug used in clinic to treat colorectal cancer and small cell lung cancer (14). It exhibits cytotoxic effects on cancer cells by interfering with the DNA replication and transcription through inhibiting the activity of topoisomerase I and thus preventing the unwinding of DNA (15). However, CPT-11 itself does not specifically target cancer cells but is also toxic to normal tissues including the intestinal epithelium (16). It has been reported that CPT-11 can be converted into 7-ethyl-10-hydroxy-camptothecin (SN-38), a more potent inhibitor of topoisomerase when compared with CPT-11, by the hepatic carboxylesterase (17). SN-38 becomes the major metabolite that is highly toxic to the intestine (18). Recent studies have identified the ileum, jejunum, and liver as the target tissues of CPT-11’s toxicity (19). Beyond its direct toxicity to the intestinal epithelial cells, it has also been shown to activate inlammosomes and IL-1β secretion through Janus N-terminal kinase and nuclear factor-kB signaling (20). Consequently, CPT-11 treatment may induce colitis as dextran sodium sulfate does (13, 20). In addition, CPT-11 may induce hyper-proliferation of mesenteric lymph node cells and hyper-production of inflammatory cytokines from them upon mitogen stimulation (21). It is known that chronic inflammation directs macrophages to polarize into M2 phenotype (22), which in turn benefits tumor growth (23–25). Indeed, CPT-11 treatment increases infiltration of macrophages and secretion of chemokines (including monocyte chemotactic protein 1) in tumor-bearing mice (26), when compared with vehicle treatment. Moreover, elimination of the peritoneal resident macrophages by CPT-11 (13) may impair the homeostasis of gastrointestinal immunity and thus weaken its actions against intestinal cancers.

Although we have demonstrated that CPT-11 can deplete the resident peritoneal macrophages (13), the dynamic details underlying this process remain unknown. For example, could the resident peritoneal macrophages and B1 cells recover from CPT-11 treatment by self-renewal? Does adoptive cell transfer benefit the recovery of these innate immune cells? In this study, we have addressed these issues by using a mouse model of CPT-11 treatment. Our results showed that the LPMs and B1 cells in the peritoneal exudate were almost fully depleted by CPT-11 within 1 week, but reappeared afterward. However, even until the end of the experiments (2 months after CPT-11 treatment), the restoring numbers of both LPMs and B1 cells were much fewer than those of vehicle-treated or untreated control groups. Adoptive transfer with syngeneic peritoneal exudate cells (PEGs) accelerated the recovery of LPMs and B1 cells, but whether transfer with bone marrow cells (BMCs) had such an effect warranted longer observation. Our data revealed a prolonged deterioration of CPT-11 on the innate immune cells in the peritoneal cavity, which should be noted in the application of CPT-11 for cancer treatment in clinic.

**MATERIALS AND METHODS**

**Reagents and Antibodies**

Dimethyl sulfoxide (D8418), Hoechst 33342 (B2261), Tween 80 (P8074), and paraformaldehyde (158127) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM) with high glucose, penicillin, streptomycin, and fetal bovine serum (FBS) were products of ThermoFisher/Gibco (Carlsbad, CA, USA). CPT-11 (#HY-16562A) was purchased from MedChem Express (Princeton, NJ, USA), dissolved in ethanol before freshly diluted in phosphate-buffered saline (PBS) containing 2% Tween 80 in each experiment, and the final concentration of ethanol, never exceeded 5%. Fluorescence-labeled monoclonal antibodies CD11b-FITC (#11-0112), F4/80-PE (#12-4801), MHCII-APC (#17-5321), CD23-PE (#12-0232), CD19-eFluor660 (#50-0193), and CD11b-AlexaFluor488 (#53-0112) were obtained from eBioscience (San Diego, CA, USA); monoclonal anti-mouse F4/80-AlexaFluor 647 (#123121) were bought from BioLegend (San Diego, CA, USA). The rabbit monoclonal antibody against GATA6 (#5851) was purchased from Cell Signaling Technology (Danvers, MA, USA). CF568 goat-anti-rabbit IgG (H+L), highly cross-adsorbed (#201031) was obtained from Biotium (Hayward, CA, USA).

**Animals**

Female C57BL/6 mice (6–8 weeks of age) were purchased from the Experimental Animal Center of Southern Medical University (Guangzhou, China). All animal experiments were performed in accordance with the guidelines for the care and use of animals.
 approved by the Committee on the Ethics of Animals Experiments of Jinan University.

After 1 week of acclimatization, mice were randomly divided into groups with six mice in each group, and administered intraperitoneally (i.p.) with vehicle, CPT-11 (200 mg/kg body weight, at day 0) or untreated (control), respectively. The mice were sacrificed at day 3, day 7, day 14, day 28, and day 56, respectively.

In another experiment, mice were i.p. injected with CPT-11 (200 mg/kg body weight). After 7 days, the mice were injected (i.p.) with viable *Escherichia coli* bacteria (1 × 10^8 CFU/mouse), which was freshly prepared as described previously (27). Their survival was observed and recorded every 6 h for four consecutive days.

Further in a separate experiment, mice were orally administered with CPT-11 (400 mg/kg body weight) once (at day 0) or twice (at day 0 and day 1), i.e., vehicle or left untreated. The mice were sacrificed at day 3, day 7, or day 14, respectively. The PECs were collected and analyzed as described below. The intestines and colons were isolated and fixed in 4% neutral formaldehyde. Paraffin slices of the tissues were stained with hematoxylin and eosin. Images were captured under a Zeiss Axio Observer D1 microscope armed with a color CCD (ZEISS).

**Isolation and Flow Cytometric Analysis of Mouse Peritoneal Cells**

After indicated treatment and being sacrificed, each mouse was injected with 1.5 ml washing buffer (germ-free PBS containing 0.5 mM EDTA and 5% calf serum) into the peritoneal cavity and the peritoneal lavage fluid was collected. The PECs were washed once with PBS-F (PBS containing 0.1% NaN3 and 3% FBS) by centrifugation at 300 × g for 5 min, and then stained with FITC labeled anti-CD11b, PE labeled anti-F4/80, and APC labeled anti-MHCII, or PE-conjugated anti-CD23 and eFluor660-conjugated anti-CD19 monoclonal antibodies at 4°C for 30 min. Red blood cells, if there were, were lysed with ACK lysis buffer (155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). After washing once with PBS-F, cells were fixed with 4% paraformaldehyde in PBS and then analyzed on a flow cytometer (FACSCalibur; Becton Dickinson). Data were acquired and analyzed by using the CELLQuest software (Becton Dickinson).

**Cell Culture and Fluorescence Microscopy**

Immunofluorescence analysis was performed essentially as previously described (28). Briefly, PECs were collected by centrifugation at 300 × g for 5 min and re-suspended in complete DMEM medium containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. Then the cells were seeded in glass-bottomed dishes (5 × 10^5 cells/dish). After 2-h incubation at 37°C in a humidified incubator of 5% CO2, unattached cells were discarded. After washed with PBS, the adherent macrophages were fixed in 4% paraformaldehyde for 15 min, and permeabilized with 2 ml cold methanol (−20°C) for 10 min. Then the cells were incubated with AlexaFluor488-CD11b (1:80), AlexaFluor647-F4/80 (1:100), and GATA6 (1:300) antibodies overnight, followed by being stained with CF568-conjugated goat-anti-rabbit IgG (1:750) for 1 h. The nuclei were revealed by Hoechst 33342 staining (5 µg/ml in PBS) for 10 min. The cells were observed by the Zeiss Axio Observer D1 microscope with a Zeiss LD Plan-Neofluar 100x/0.6 Korr M27 objective len (Carl Zeiss MicroImaging GmbH, Göttingen, Germany). Fluorescence images were captured and analyzed by the Zeiss ZEN software.

**Syngeneic Adoptive Transfer with Peritoneal Exuded Cells and BMCs**

Peritoneal exudate cells were collected with 2 ml washing buffer (germ-free PBS containing 0.5 mM EDTA and 5% calf serum), centrifuged at 300 × g for 5 min at 4°C, and then washed once with 2 ml cold PBS. The cells were re-suspended in PBS at 2 × 10^6 cells/ml, being ready for transplantation.

In preparing BMSs, the bone marrow from hind femora was flushed out with 10 ml of sterile cold PBS and the cells were collected by centrifugation at 300 × g for 5 min at 4°C. Red blood cells were lysed in ACK lysis buffer for 10 min at 37°C, stopped with cold DMEM containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were washed once with 2–3 ml cold PBS, and then re-suspended in PBS to 2 × 10^6 cells/ml. All procedures were performed in an aseptic surrounding.

Mice were i.p. treated with CPT-11 for 7 days, and then 0.5 ml of peritoneal exuded cells (1 × 10^6 cells) or BMCs (1 × 10^7 cells) were injected into the peritoneal cavity. After additional 21 days, the mice were sacrificed and their PECs were collected and analyzed by flow cytometry and immunofluorescence microscopy, respectively.

**Statistical Analysis**

All experiments were performed three times independently, with one representative experiment shown. Data were expressed as mean ± SD. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). One-way analysis of variance followed by Tukey post hoc test and unpaired Student’s t-test were used to analyze the statistical significance among multiple groups and between two groups, respectively. Kaplan–Meier survival curves were adopted for analysis of mice survival, and the statistical difference between two groups was determined using the log-rank (Mantel–Cox) test. P-values < 0.05 were considered statistically significant.

**RESULTS**

**The Rapid Impairment of Resident Peritoneal Macrophages after i.p. CPT-11 Treatment Required a Prolonged Recovery Period**

The dynamic process of CPT-11-induced damage to the peritoneal macrophages was assessed in mice administered with CPT-11 (i.p.). After CPT-11 treatment, the phenotypes of the PECs from the mice of each group were analyzed every week by flow cytometry. The LPMs (F4/80^-MHC-II^-) and SPMs (F4/80^+MHC-II^+) were gated and their ratios and numbers were determined, respectively (Figure 1A). The results showed...
that neither the ratios nor the numbers of LPMs and SPMs were significantly changed by vehicle when compared with untreated control. In contrast, the ratios and numbers of LPMs were greatly decreased by CPT-11 treatment. Notably, LPMs in CPT-11-treated group were hardly detectable at day 7. However, the numbers of SPMs were not significantly changed by CPT-11, despite their increased ratios within the CD11b+ population (Figures 1B, C). Together with previous studies (13), these results indicated that the resident peritoneal macrophages were rapidly depleted by i.p. CPT-11 treatment.

Next, we sought to explore the recovery dynamic process of resident peritoneal macrophages after CPT-11 treatment. Flow cytometry revealed that LPMs were detected again at day 14 and from then on their numbers were gradually increased (Figure 2A). However, although the ratios of LPMs in CPT-11 groups were time-dependently increased, their cell numbers were still much lower than those of vehicle-treated control group. The cell numbers of LPMs in CPT-11-treated group were ~30% of that in vehicle-treated control group even after 56 days. Again, the numbers of SPMs (F4/80lowMHC-IIhi) were barely influenced by CPT-11 treatment (Figures 2A, B). These results indicated that CPT-11 administration had prolonged deleterious effects on the resident peritoneal macrophages.

### The Dynamic Process of GATA6 Expression in Peritoneal Macrophages after i.p. CPT-11 Treatment

To verify the flow cytometric data showing that LPMs can be recovered from CPT-11 treatment, we next used immunofluorescent staining to detect the expression of GATA6, a functional marker of LPMs (9), in PECs. The PECs were cultured ex vivo. The macrophages among them were attached to the culture dish thus being selected by discarding the non-adherent cells, and were further observed by immunofluorescence microscopy using antibodies against CD11b, F/80, and GATA6. As shown in Figure 3A, the expression of GATA6 was not significantly influenced by vehicle treatment; but after CPT-11 treatment, the cells expressing GATA6 were drastically decreased at day 3 and were barely detectable at
The cell numbers of large peritoneal macrophages (LPMs) began to recover 2 weeks after CPT-11 treatment. (A) C57BL/6 mice (six mice per group) were injected intraperitoneally with CPT-11 at a dose of 200 mg/kg body weight. The composition of LPMs and small peritoneal macrophages (SPMs) after CPT-11 treatment was analyzed by flow cytometry using fluorescent-conjugated antibodies against CD11b, F4/80, and MHC II. (B) Cell numbers of the LPM and SPM populations were calculated as Figure 1. n = 6; *P < 0.05; ***P < 0.001; ns, not significant.

The Dynamic Process of Peritoneal B Cells after i.p. CPT-11 Treatment

Apart from resident macrophages, B cells, particularly B1 cells constitute another major population of the PECs. Thus, we next assayed the dynamic process of these cells after CPT-11 treatment. The PECs were stained with CD19 and CD23 antibodies, and analyzed by flow cytometry. Among them, B1 cells were identified as CD19+CD23− cells while B2 cells as CD19+CD23+ ones. The results showed that the numbers of B cells (CD19+) were not significantly changed by vehicle treatment when compared with untreated control (data not shown), but were greatly reduced by CPT-11. Three days after CPT-11 treatment, only ~3% of the PECs were B cells (Figures 4A,B). Consequently, the numbers of total B cells as well as B1 and B2 cells were restored at day 56, comparable with that of vehicle-treated group (Figure 4). These results demonstrated that the peritoneal B cells were quickly impaired by CPT-11 treatment but were recoverable within 2 months.

Quantification of immunofluorescent observation showed that the percentages of GATA6+ macrophages were rapidly decreased within 1 week by CPT-11 treatment but slowly recovered after day 14 (Figure 3B), which was consistent with the flow cytometric analysis of LPMs (Figures 1B and 2B). Notably, although the percentage of GATA6+ LPMs in CPT-11-treated group (day 56) was comparable with the counterpart of corresponding vehicle-treated control group, their absolute cell counts (~7.5 x 10⁶ PECs) were much fewer than the latter group (~1.5 x 10⁷ PECs). These results also showed that CPT-11 administration induced a rapid loss but a very slow recovery of the functional LPMs with GATA6 expression, indicating a prolonged deterioration of these innate immune cells in the peritoneal cavity of mice.
FIGURE 3 | Continued
**Figure 4** | The dynamic process of peritoneal B cells after CPT-11 treatment. (A) C57BL/6 mice were injected intraperitoneally with CPT-11 at a dose of 200 mg/kg body weight. The peritoneal exudate cells (PECs) were stained with antibodies against CD19 and CD23 and then analyzed by flow cytometry. B1 cells were identified as CD19$^{+}$CD23$^{-}$ cells and B2 as CD19$^{+}$CD23$^{+}$ ones. (B–D) The numbers of total B (CD19$^{+}$) (B), B1 (CD19$^{+}$CD23$^{-}$) (C), and B2 (CD19$^{+}$CD23$^{+}$) (D) cells were calculated by their percentages times the total PEC numbers (determined by a hemocytometer), respectively. $n = 6$; *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$; ns, not significant.
Adoptive Transfer of Syngeneic PECs Accelerated the Recovery Processes of LPMs and B1 Cells in the i.p. CPT-11-Treated Mice

As CPT-11 treatment rapidly reduced the numbers of both LPMs and B cells within 1 week but the recovery processes were slow, we next sought to explore whether adoptive cell transfer accelerated the recovery processes. Mice were received syngeneic PECs and BMCs at day 7 after CPT-11 treatment. The phenotypes of the PECs were analyzed 21 days after the adoptive transfer. The results showed that the adoptive transfer with PECs significantly increased the ratios and numbers of LPMs (F4/80\textsuperscript{hi}-MHC-II\textsuperscript{lo}) in CPT-11-treated mice when compared with those of CPT-11-treated control group without adoptive transfer, although these values were still lower than those of vehicle-treated control group. The adoptive transfer with BMCs also slightly increased the numbers of LPMs when compared with those of CPT-11-treated group without adoptive transfer, but the differences were not statistically significant (Figures 5A,B). Besides, the ratios and numbers of SPMs were not significantly changed by the adoptive PECs or BMCs (Figures 5A,C).

Consistent with the flow cytometry analysis, immunofluorescence microscopy also revealed that GATA6 expression in the peritoneal macrophages was greatly suppressed by CPT-11 treatment, but transfer of PECs into the peritoneal cavity significantly increased the percentage of GATA6\textsuperscript{+} macrophages when compared with CPT-11-treated control group (Figures 6A,B). The adoptive transfer of BMCs also increased GATA6 expression, although this was not statistically significant (Figure 6B).

Similarly, the adoptive transfer of PECs also rescued the B cell population (including B1 and B2 subpopulations) in the peritoneal cavity of the CPT-11-treated mice. However, transfer of BMCs was unlikely to help the recovery of B cell counts that had been decreased by CPT-11 treatment (Figure 7). Together, the adoptive transfer of PECs, instead of BMCs, promoted the recovery of resident peritoneal macrophages and B cells in CPT-11-treated mice.

i.p. Treatment with CPT-11 Reduced Mouse Survival Rate against Bacterial Infection

We next explored the functional consequence of the impairment of resident peritoneal macrophages in CPT-11-administered

**FIGURE 5** | Syngeneic adoptive transfer with peritoneal exudate cells (PECs) rescued the resident peritoneal macrophages after CPT-11 treatment. C57BL/6 mice were intraperitoneally injected with CPT-11 (200 mg/kg body weight, in phosphate-buffered saline containing 2% Tween-80) or vehicle. Seven days later, the CPT-11 group mice were transferred with syngeneic PECs (1 x 10\textsuperscript{6}/mouse) or bone marrow cells (BMCs, 1 x 10\textsuperscript{7}/mouse). The mice were cultivated for 21 days more, and then their PECs were analyzed by flow cytometry after being stained with fluorescent-conjugated antibodies against CD11b, F4/80, and MHC II. (A) A representative set of flow cytometric dot-plots was presented. (B,C) The numbers of large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs) were calculated by their percentages times the total peritoneal cell numbers (determined by a hemocytometer), respectively, n = 6; *P < 0.05; ***P < 0.001; ns, not significant.
mice. The mice were first i.p. injected with CPT-11 and 7 days later their peritoneal cavity were infected with viable *E. coli*. As shown in Figure 8, CPT-11 treatment significantly reduced the mouse survival rate when compared with that of vehicle-treated or untreated control groups. This suggested that the reduction of peritoneal macrophages and B cells upon CPT-11 treatment had significantly weakened the innate immunity against bacterial infection.

**Oral Administration of CPT-11 Induced a Delayed Toxicity to the Peritoneal Macrophages When Compared with i.p. Treatment**

Oral administration of CPT-11 has been shown to be active against tumors in nude mice (29), but most of the animal experiments using CPT-11 were performed by i.p. injection according to the protocol of Battelle Columbus laboratories, which has displayed similar pharmacokinetics to those by intravenous (i.v.) administration (29, 30). In this study, we investigated whether CPT-11 by oral intake also changed the components of the PECs and induced intestinal inflammation in mice as it does by i.p. injection (20, 31). Different from i.p. route, oral administration of CPT-11 twice (at day 0 and day 1) at the dose of 400 mg/kg in C57BL/6 mice did not significantly reduced the percentages of peritoneal macrophages (LPMs and SPMs) (Figure S1 in Supplementary Material) and of B cells (Figure S2 in Supplementary Material) at day 3. Nor did it changed the expression of GATA6 in the peritoneal macrophages (Figure S3 in Supplementary Material). However, the total peritoneal exude cells reduced about one-third (from ~1.5 × 10^6 to ~9.5 × 10^5). Moreover, oral CPT-11 administration induced severe epithelial vacuolation in the full-length of the intestines (Figure S4 in Supplementary Material) and the animals began to die from day 4 and on (data not shown).

In another experiment, the drug was administered orally at the same dose only once (at day 0). The total number of the PECs in the CPT-11 group were decreased to ~9 × 10^5 (~1/3 reduction when compared with vehicle-treated or untreated control) at both day 7 and day 14. Again, oral CPT-11 treatment did not change the percentages of peritoneal macrophages at day 7 (data not shown), but those of LPMs were decreased by CPT-11 at day 14 (Figure S5 in Supplementary Material). The ratios and numbers of peritoneal B cells were unchanged until day 14, except that the percentages of B2 cells seemed increased by CPT-11 at day 14 (Figure S6 in Supplementary Material). However, the expres-
sion of GATA6 in the peritoneal macrophages was unchanged (Figure S7 in Supplementary Material). Therefore, in addition to induction of exaggerated intestinal inflammation, oral CPT-11 administration showed a delayed cytotoxicity to the peritoneal macrophages when compared with i.p. CPT-11 treatment.

**DISCUSSION**

CPT-11 is used as a first-line drug for colorectal cancer treatment in clinic. However, there are reports indicating that CPT-11 is also toxic to the intestinal epithelium and peritoneal innate immune cells (13, 16, 32), while i.v. CPT-11 usually induces vomiting and neutropenia in patients (33).

In this study, we demonstrated the prolonged influences of CPT-11 on mouse resident peritoneal macrophages and B1 cells. After CPT-11 treatment, the whole populations of F4/80^hi^GATA6^+^ macrophages (i.e., LPMs) and CD19^+^CD23^+^ B1 cells were almost completely depleted. LPMs were hardly detectable at day 7 after
CPT-11 treatment, but reappeared at day 14. However, the recovery process was slow in that the peritoneal macrophages were not completely recovered within 2 months.

Resident peritoneal macrophages are self-renewing from their progenitors in the omentum (3, 34). If without the existing progenitors, the self-renewal of resident peritoneal macrophages should be hampered. Thus, the slow recovery process of LPMs was likely due to severe damage to their self-renewing progenitors after CPT-11 treatment. A minor remnant of these self-renewing progenitors may survive CPT-11 treatment and slowly replenish the LPMs. On the other hand, it has been demonstrated that bone marrow-derived (circulating) monocytes can enter into the peritoneal cavity, becoming $F4/80^{\text{hi}}\text{MHCII}^+$ macrophages (phenocopying the SPMs) (7), and the latter can be further developed into $F4/80^{\text{hi}}\text{GATA6}^+$ macrophages (5). Although LPMs are self-renewing in the steady state, they can be reconstituted by
In that report, our data revealed that the recovery process of
B1 cells are responsible for the maintenance of gastrointestinal
epithelium (39). Therefore, resident peritoneal macrophages and
effectively prevent pathogens from invading into the intestinal
IgA, can survive in the harsh intestinal tract environment and
B1 cells and promote the latter to migrate into the intestine and
Many studies have focused on the undesirable toxicity of
CPT-11 on normal tissues in humans beyond its cytotoxic effects
on cancer cells (36). It has been shown that CPT-11 can induce
diarrhea and vomiting (37). Although it is unknown whether
depletion of the peritoneal macrophages by CPT-11 contributed
to these side effects, the toxicity of CPT-11-treated mice was also
slow as only one-third of normal cell numbers were recovered
after 2 months of CPT-11 treatment. However, it is still
unclear whether the reappeared LPMs were developed from
the circulating monocytes or the remnant of their self-renewing
progenitors in the omentum in the context of our experimental
setting. Further study is required to clarify this issue.

CPT-11 is used in humans by i.v. injection. While in mouse
experiments, CPT-11 is usually administered by i.p. injection
according to the protocol of Battelle Columbus laboratories
(29, 30). Although i.p. administration of CPT-11 is regarded
as a usual route in mice to mimic the i.v. injection in humans
(29, 30), oral gavage has also been used in animal studies (29).
Thus, it is worth to know whether oral administration of CPT-
11 also impairs the peritoneal innate immunity. To address this
issue, mice were orally administered with CPT-11 once (at day 0)
or twice (at day 0 and day 1). Interestingly, the total PECs were
reduced about one-third as detected at day 3 (CPT-11 once or
twice), but were not further reduced at day 7 or day 14 (CPT-11
once). When compared with the i.p. treatments, oral administra-
tion induced a delayed toxicity to the peritoneal macrophages
as the percentages and numbers of LPMs were significantly
reduced at day 14. Notably, oral administration twice with CPT-
11-induced severe intestinal epithelial vacuolation and the mice
began to die from day 4 (so only the data of day 3 were shown).
Thus, oral CPT-11 treatment seemed less toxic to the peritoneal
cells, but had elicited severe intestinal inflammation, which may
have hampered its potential use by oral route.

As peritoneal innate immune cells play a fundamental role
in gastrointestinal homeostasis, it is worth to explore whether adop-
tive cell transfer could accelerate the recovery of the peritoneal
innate immune cells after CPT-11 administration. Consistent
with previous studies that the F4/80hi macrophages can be reconstituted by circulating monocytes (7) or donor bone
marrow (5), our current studies showed that the recovery of
F4/80hi GATA6+ macrophages in CPT-11-treated mice was also
slow as only one-third of normal cell numbers were recovered
after 2 months of CPT-11 treatment. However, it is still
unclear whether the reappeared LPMs were developed from
the circulating monocytes or the remnant of their self-renewing
progenitors in the omentum in the context of our experimental
setting. Further study is required to clarify this issue.

CPT-11 induced impairment of the peritoneal innate immune cells may weaken the first line of defense
against infections. Indeed, the i.p. treatment with CPT-11 had
greatly reduced the survival rate of mice upon bacterial infec-
tion. In this sense, the toxicity of CPT-11 on these innate immune
cells may do great harm to the homeostasis of the gastrointestinal
innate immunity.

CPT-11 is used in humans by i.v. injection. While in mouse
experiments, CPT-11 is usually administered by i.p. injection
according to the protocol of Battelle Columbus laboratories
(29, 30). Although i.p. administration of CPT-11 is regarded
as a usual route in mice to mimic the i.v. injection in humans
(29, 30), oral gavage has also been used in animal studies (29).
Thus, it is worth to know whether oral administration of CPT-
11 also impairs the peritoneal innate immunity. To address this
issue, mice were orally administered with CPT-11 once (at day 0)
or twice (at day 0 and day 1). Interestingly, the total PECs were
reduced about one-third as detected at day 3 (CPT-11 once or
twice), but were not further reduced at day 7 or day 14 (CPT-11
once). When compared with the i.p. treatments, oral administra-
tion induced a delayed toxicity to the peritoneal macrophages
as the percentages and numbers of LPMs were significantly
reduced at day 14. Notably, oral administration twice with CPT-
11-induced severe intestinal epithelial vacuolation and the mice
began to die from day 4 (so only the data of day 3 were shown).
Thus, oral CPT-11 treatment seemed less toxic to the peritoneal
cells, but had elicited severe intestinal inflammation, which may
have hampered its potential use by oral route.

As peritoneal innate immune cells play a fundamental role
in gastrointestinal homeostasis, it is worth to explore whether adop-
tive cell transfer could accelerate the recovery of the peritoneal
innate immune cells after CPT-11 administration. Consistent
with previous studies that the F4/80hi macrophages can be reconstituted by circulating monocytes (7) or donor bone
marrow (5), our current studies showed that the recovery of
F4/80hi peritoneal macrophages and B1 cells was accelerated by
adoptive transfer of syngeneic PECs. Although it remains to be
investigated whether such cell transplantation could attenuate the
adverse toxicity of CPT-11, the adoptive transfer of PECs may be
of translational significance for cancer treatment using CPT-11.
Both the resting peritoneal macrophages and B1 cells are long-
lived cells and can be isolated, if necessary, from cancer patients
and be cryo-preserved for later use. Being revived in vitro, the
peritoneal macrophages or B1 cells may be transplanted back into
the peritoneal cavity after CPT-11 chemotherapy to accelerate the
recovery of the peritoneal macrophages and B1 cells.

It should be noted that being different from the transplanta-
tion of PECs, the adoptive transfer of BMCs only slightly but not
significantly increased the numbers of LPMs and B1 cells. This
may be because the transition of donor BMCs into LPM-like
macrophages or B1-like cells in the peritoneal cavity needs a
longer period, as has been suggested previously (5, 40). Therefore,
longer observation is warranted to learn whether autologous
BMCs can be developed into LPMs and B1 cells in the peritoneal
cavity. Another possibility is that adult BMCs were recruited in
this study. Previous reports have suggested that aged BMCs have
lost their ability to differentiate into peritoneal B1 cells (40).
In summary, i.p. CPT-11 treatment induced the depletion of resident peritoneal macrophages (LPMs) and B cells (including B1 and B2 cells), but the recovery processes of these cells were slow. Adoptive transfer with syngeneic PECs into the CPT-11-treated peritoneal cavities accelerated the recovery of these innate immune cells. Although further functional studies are needed, our studies highlight the potential of adoptive cell transfer as a way to counteract the adverse effects of this chemotherapeutic agent.

ETHICS STATEMENT

Female C57BL/6 mice (6–8 weeks of age) were purchased from the Experimental Animal Center of Southern Medical University (Guangzhou, China). All animal experiments were performed in accordance with the guidelines for the care and use of animals approved by the Committee on the Ethics of Animals Experiments of Jinan University.

REFERENCES

1. Kawahara T, Ohdan H, Zhao G, Yang Y-G, Sykes M. Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J Immunol (2003) 171:5406–14. doi:10.4049/jimmunol.171.10.5406
2. Wang C, Yu X, Cao Q, Wang Y, Zheng G, Tan TK, et al. Characterization of murine macrophages from bone marrow, spleen and peritoneum. BMC Immunol (2013) 14:6. doi:10.1186/1471-2172-14-6
3. Cassado Ados A, D’Imperio Lima MR, Bortoluci KR. Revisiting mouse peritoneal macrophages: heterogeneity, development, and function. Front Immunol (2015) 6:225. doi:10.3389/fimmu.2015.00225
4. Liao C-T, Andrews R, Wallace LE, Khan MW A, Kift-Morgan A, Topley N, et al. Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney Int (2017) 91:1088–103. doi:10.1016/j.kint.2016.10.030
5. Bain CC, Hawley CA, Garner H, Scott CL, Schridde A, Steers NJ, et al. Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities. Nat Commun (2016) 7:ncomms11852. doi:10.1038/ncomms11852
6. Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A (2010) 107:2568–73. doi:10.1073/pnas.0915000107
7. Kim KW, Williams JW, Wang YT, Ivanov S, Gilfillan S, Colonna M, et al. MHC II+ resident peritoneal and pleural macrophages rely on IRF4 for development from circulating monocytes. J Exp Med (2016) 213:1951–9. doi:10.1084/jem.20160486
8. Wang H, Lin JX, Li P, Skinner J, Leonard WJ, Morse HC III. New insights into heterogeneity of peritoneal B-1a cells. Ann N Y Acad Sci (2015) 1362:67–88. doi:10.1111/nyas.12791
9. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell (2014) 157:832–44. doi:10.1016/j.cell.2014.04.016
10. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2011) 11:34–46. doi:10.1038/nri2901
11. Kelly-Scumpia KM, Scumpia PO, Weinstein JS, Delano MJ, Cuenca AG, Nacionales DG, et al. B cells enhance early innate immune responses during bacterial sepsis. J Exp Med (2011) 208:1673–82. doi:10.1084/jem.20101715
12. Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC, et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science (2014) 345:645–8. doi:10.1126/science.1251414

AUTHOR CONTRIBUTIONS

W-JB, L-HX, C-CZ, BH, and ZH conducted animal studies; W-JB, C-GL, L-HX, and Q-ZZ performed flow cytometry and immunofluorescence assays; W-JB and C-GL analyzed the data; D-YO and X-HH supervised the study; and D-YO, X-HH, and W-JB wrote the paper.

FUNDING

This work was supported by the grants from the National Natural Science Foundation of China (no. 81373423, no. 81673664, and no. 81773965).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2017.01919/full#supplementary-material.

13. Huang MY, Pan H, Liang YD, Wei HX, Xu LH, Zha QB, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis (2016) 21:130–42. doi:10.1007/s10495-015-1193-2
14. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol (2010) 17:421–33. doi:10.1016/j.chembiol.2010.04.012
15. Eder JP, Chen V, Wong J, Wong YW, Ara G, Northeay D, et al. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol (1998) 42:327–35. doi:10.1007/s002800050825
16. Roberts AB, Wallace BD, Venkatesh MK, Redinbo MR. Molecular insights into microbial beta-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol (2013) 84:208–17. doi:10.1124/mol.113.085852
17. Satoh T, Yasu H, Muro K, Komatsu Y, Sameshima S, Yamaguchi K, et al. Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a sub study of the FIRIS study. Anticancer Res (2013) 33:3845–53.
18. Yamamoto M, Kurita A, Asahara T; Takakura A, Katono K, Iwashki M, et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep (2008) 20:727–30. doi:10.3892/or_0000066
19. Yao Y, Zhang P, Wang J, Chen J, Wang Y, Huang Y, et al. Dissecting target toxic tissue and tissue specific responses of irinotecan in rats using metabolomics approach. Front Pharmacol (2017) 8:122. doi:10.3389/fphar.2017.00122
20. Li Q, Zhang X, Wang W, Li L, Xu Q, Wu X, et al. CPT-11 activates NLRP3 inflammasome through NLR and NF-kB signalings. Toxicol Appl Pharmacol (2015) 289:133–41. doi:10.1016/j.taap.2015.09.025
21. Xue H, Field C, Sawyer M, Dielemann L, Baracos V. Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer (2009) 101:1581–8. doi:10.1038/sj.bjc.6605051
22. Liu YC, Zou YM, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci (2014) 10:529. doi:10.7150/ijbs.8879
23. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep (2016) 15:2000–11. doi:10.1016/j.celrep.2016.04.084
24. Takaihi K, Komohara Y, Tashiro H, Katabuchi H, Takaishi K, Komohara Y, Tashiro H, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer (2016) 19:1052–65. doi:10.1007/s10120-015-0579-8
26. Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, et al. Interaction of a traditional Chinese medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. *BMC Med Genomics* (2011) 4:38. doi:10.1186/1755-8794-4-38

27. Zha QB, Wei BX, Li CG, Liang YD, Xu LH, Bai WJ, et al. ATP-induced inflammasome activation and pyroptosis is regulated by AMP-activated protein kinase in macrophages. *Front Immunol* (2016) 7:597. doi:10.3389/fimmu.2016.00597

28. Pan H, Xu LH, Huang MY, Zha QB, Zhao GX, Hou XF, et al. Piperine metabolically regulates peritoneal resident macrophages to potentiate their functions against bacterial infection. *Oncotarget* (2015) 6:32468–83. doi:10.18632/oncotarget.5957

29. Choi SH, Tsuchida Y, Yang HW. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. *Cancer Lett* (1998) 124:15–21. doi:10.1016/S0304-3835(97)00428-X

30. Kaneko S, Ishibashi M, Kaneko M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts. *Cancer Sci* (2008) 99:1209–17. doi:10.1111/j.1349-7006.2008.00790.x

31. Wardill HR, Gibson RJ, Van Sebille YZ, Secombe KR, Coller JK, White IA, et al. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. *Mol Cancer Ther* (2016) 15:1376–86. doi:10.1158/1535-7163.mct-15-0990

32. Ong SY, Clarke SJ, Bishop J, Dodds HM, Rivory LP. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. *Anticancer Drugs* (2001) 12:619–25. doi:10.1097/00001813-200108000-00009

33. Rougier P, Bugat R, Douillard JY, Caline S, Suc E, Brunet P, et al. The adaptor protein Myd88 is a key signaling molecule in the pathogenesis of irinotecan-induced intestinal mucositis. *PLoS One* (2015) 10:e0139985. doi:10.1371/journal.pone.0139985

34. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* (2013) 38:792–804. doi:10.1016/j.immuni.2013.04.004

35. Cain DW, O’Koren EG, Yan M, Wombke M, Sempowski GD, Hopper K, et al. Identification of a tissue-specific, C/EBPβ-dependent pathway of differentiation for murine peritoneal macrophages. *J Immunol* (2013) 191:4665–75. doi:10.4049/jimmunol.1300581

36. Wang J, Kubes P. A reservoir of mature cavity macrophages that can rapidly invade visceral organs to affect tissue repair. *Cell* (2016) 165:668–78. doi:10.1016/j.cell.2016.03.009

37. Swami U, God S, Mani S. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. *Curr Drug Targets* (2013) 14:777–97. doi:10.2174/1389450111314070007

38. Mantis NJ, Rol N, Conolly B. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. *Mucosal Immunol* (2011) 4:603–11. doi:10.1038/mi.2011.41

39. Hayakawa K, Hardy RR, Herzenberg LA, Herzenberg LA. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. *J Exp Med* (1985) 161:1554–68. doi:10.1084/jem.161.6.1554

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Bai, Li, Zhang, Xu, Zeng, Hu, Hong, He and Ouyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.